| Baseline | Week 4 |
---|
vWF skin | 4738 ± 1353 | 430 ± 158** |
vWF synovium | 93121 ± 26511 | 32739 ± 7152* |
αvβ3 skin | 9780 ± 1631 | 3580 ± 518** |
αvβ3 synovium | 2003 ± 684 | 274 ± 97* |
VEGF skin | 8230 ± 1651 | 5675 ± 1700 |
VEGF synovium | 1784 ± 540 | 674 ± 236 |
- Blood vessels positive for von Willebrand factor (vWF; all blood vessels) and αvβ3 (newly formed blood vessels) as well as expression of vascular endothelial growth factor (VEGF; integrated optical density/mm2) before and 4 weeks after initiation of infliximab therapy. The data are expressed as mean ± standard error of the mean. *P ≤ 0.05, **P ≤ 0.02, versus baseline.